Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Paradigm Biopharmaceuticals Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.57K | 52.12K | 65.80K | 46.76K | 79.22K | 20.55K |
| Gross Profit | -97.57K | -19.89K | 56.81K | -18.83K | -64.53K | -78.59K |
| EBITDA | -40.72M | -25.25M | -64.54M | -59.06M | -46.82M | -42.40M |
| Net Income | -36.09M | -18.77M | -58.65M | -51.91M | -39.25M | -34.30M |
Balance Sheet | ||||||
| Total Assets | 23.15M | 24.57M | 27.39M | 67.07M | 50.69M | 84.79M |
| Cash, Cash Equivalents and Short-Term Investments | 14.66M | 16.82M | 17.87M | 56.38M | 39.72M | 71.08M |
| Total Debt | 1.01M | 5.48K | 239.33K | 341.67K | 616.67K | 751.84K |
| Total Liabilities | 17.16M | 3.39M | 3.58M | 13.39M | 8.38M | 6.52M |
| Stockholders Equity | 6.00M | 21.18M | 23.81M | 53.68M | 42.31M | 78.27M |
Cash Flow | ||||||
| Free Cash Flow | -7.77M | -15.99M | -65.94M | -45.19M | -32.21M | -34.96M |
| Operating Cash Flow | -27.42M | -15.99M | -65.94M | -45.19M | -32.21M | -34.93M |
| Investing Cash Flow | -567.20K | 46.20K | 0.00 | 0.00 | 0.00 | 668.37K |
| Financing Cash Flow | 18.17M | 14.99M | 28.18M | 62.53M | 70.12K | 1.00M |
Paradigm Biopharmaceuticals Technical Analysis
Paradigm Biopharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$156.16M | -4.74 | ― | ― | ― | 0.66% | |
52 Neutral | AU$98.99M | -11.71 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$114.21M | -2.91 | -81.03% | ― | -20.79% | 73.98% | |
42 Neutral | AU$77.16M | -1.07 | -83.09% | ― | ― | 55.94% | |
42 Neutral | AU$64.27M | -3.13 | -247.98% | ― | ― | ― | |
41 Neutral | AU$87.00M | -6.67 | -42.68% | ― | ― | 63.46% |
Paradigm Biopharmaceuticals Corporate Events
Paradigm Biopharmaceuticals reported a net loss before tax of A$23.2 million for the half-year ended 31 December 2025, a sharp increase from the prior period’s A$5.9 million loss, as it intensified investment in late-stage clinical development. The company’s revenue from continuing activities fell 34.5% to A$284,055, basic and diluted loss per share widened to 5.62 cents, and net tangible asset backing dropped to 1.19 cents per share, underscoring the financial impact of sustained Phase 3 trial spending in the absence of commercial income.
No dividends were declared for the period, reflecting Paradigm’s focus on funding its clinical pipeline rather than returning capital to shareholders. The results highlight the company’s reliance on external funding while it progresses iPPS through crucial Phase 3 and regulatory milestones, a strategy that may increase near-term losses but is intended to position Paradigm for potential future commercialisation if trials are successful.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s interests in the company’s securities, detailing movements across fully paid ordinary shares, listed options, performance rights and unlisted piggyback options. The update, filed under ASX listing rules, provides investors with transparency on the director’s direct and indirect holdings, including those held via self‑managed superannuation and family trust structures, and reflects ongoing adjustments to his equity exposure in the company.
The notice outlines the expiry dates and exercise prices associated with the various classes of securities, confirming both existing positions and newly acquired or granted instruments. This level of disclosure helps shareholders assess potential alignment between executive incentives and long‑term company performance, while signalling the scale and structure of a key director’s stake in Paradigm Biopharmaceuticals.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s interests, reporting the lapse of 354,958 listed options exercisable at $0.65 that expired on 11 February 2026. Following the lapse, Fry continues to hold 1,419,830 fully paid ordinary shares, with no consideration involved in the change and no trading during a closed period, indicating a routine update to the company’s director interest register without immediate operational impact.
The announcement reflects ongoing compliance with ASX listing rules and the Corporations Act, ensuring transparency around director holdings for investors and regulators. While the lapse slightly reduces Fry’s potential future equity exposure, it does not alter the company’s existing share count and primarily serves to keep the market accurately informed about board-level securities positions.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan polysulfate sodium in dogs with naturally occurring osteoarthritis has been published in the peer-reviewed journal PLOS One. The collaborative trial with the University of Melbourne assessed a six-week course of subcutaneous PPS in companion dogs with established joint disease of the stifle and elbow, using pain scores, gait analysis, MRI and serum biomarkers over a 26-week follow-up.
The randomized, placebo-controlled exploratory study showed that PPS-treated dogs had sustained reductions in chronic pain through 26 weeks, while placebo-treated dogs experienced worsening pain. Objective gait analysis demonstrated progressive normalization of gait symmetry and improved weight bearing in the PPS group, indicating better joint function and reduced lameness.
MRI data revealed stabilization and modest increases in cartilage volume in PPS-treated dogs at weeks 8 and 26, compared with continued cartilage loss in the placebo group. Together with changes in bone and cartilage turnover biomarkers, these structural results support a potential disease-modifying effect of PPS and strengthen the relevance of the canine osteoarthritis model as a translational analogue for longer-term human outcomes.
The publication provides peer-reviewed validation that PPS can deliver durable clinical, functional and structural benefits in a model of naturally occurring, age-related osteoarthritis highly regarded by the pharmaceutical industry. This supports Paradigm’s positioning of PPS as a candidate disease-modifying therapy for osteoarthritis and may bolster confidence among regulators, clinicians and investors in the company’s late-stage development strategy.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has signed a binding term sheet with AVet Health to co-develop and license an oral combination of pentosan polysulfate sodium and a COX-2 inhibitor for osteoarthritis in companion animals in Australia and New Zealand. AVet will hold exclusive rights in those markets and a first right of refusal in most other territories, while Paradigm retains U.S. veterinary rights and potential development milestones of up to A$1 million.
Once a definitive licensing agreement is executed, Paradigm will control manufacturing and earn tiered royalties of up to 20 percent on net sales over a 15-year term following Australian registration. The partnership enables Paradigm to advance this first-in-class, dual-action veterinary OA therapy and generate early data in a capital-efficient way, supporting both veterinary commercialization and its broader osteoarthritis strategy alongside the pivotal Phase 3 Zilosul trial.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has disclosed a change in the interests of director Paul Rennie, who has converted 153,265 listed options into fully paid ordinary shares. The transaction, executed on 3 February 2026 for a consideration of $99,622.25, increases Rennie’s direct holding of ordinary shares while reducing his listed options by the same amount, signalling a shift from derivative exposure to outright equity ownership and marginally strengthening insider alignment with ordinary shareholders.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has applied to the ASX for quotation of 176,880 new ordinary fully paid shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 3 February 2026. The modest increase in quoted securities slightly expands the company’s capital base and free float, reflecting ongoing utilisation of equity-linked instruments but not indicating any major change to its operational strategy or market positioning at this time.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 10,037 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects routine capital management and slightly expands the company’s listed share base, with limited direct impact on its overall capital structure but maintaining flexibility for ongoing funding of operations and development activities.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals reported continued operational progress in the December 2025 quarter, advancing its global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis pain, with most sites in Australia and the United States now active and additional locations in Hong Kong and Moldova set to commence screening to bolster recruitment and geographic diversity. The company highlighted that Hong Kong participation aligns with a new regulatory pathway that could support future registration flexibility, while the publication of Phase 2 biomarker data in a leading peer-reviewed journal provides important external validation of iPPS’s biological effects and underpins regulatory and commercial engagement, alongside a solid cash position and further translational work in canine osteoarthritis designed to strengthen the scientific case for its lead asset.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 35,544 new ordinary fully paid shares, to be issued on 27 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest share issuance marginally increases the company’s quoted capital base and reflects ongoing utilisation of equity-linked incentives or financing structures, with limited immediate dilution for existing shareholders but signalling continued capital management activity as the company pursues its biopharmaceutical development objectives.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 4,940,912 new fully paid ordinary shares, following the exercise or conversion of options or other convertible securities. The issuance and listing of these additional shares modestly increases the company’s free float and share capital, potentially enhancing liquidity for investors and signaling ongoing utilisation of equity-linked incentives or financing instruments.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has advised holders of its PAROA quoted options that 97,358,215 options will expire at 5pm AEDT on 11 February 2026, with trading in these options to cease on 5 February 2026. Option holders have been notified that each option is exercisable at $0.65 into fully paid ordinary shares, with the potential issue of an equal number of shares and 48,679,107 piggyback options exercisable at $1.00 by February 2028, although the current share price of $0.35 sits below the exercise price; any options not exercised with cleared funds by the deadline will lapse unexercised, and there is no underwriting in place, leaving final take-up entirely dependent on investor demand.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
Paradigm Biopharmaceuticals has confirmed it has enrolled or randomised enough patients to meet the 25% recruitment threshold in its pivotal global Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis, with some participants scheduled to begin dosing after the holiday period to safeguard protocol compliance over the six-week regimen. The company reports strong screening activity, boosted by a targeted Medimark-led outreach campaign in Australia that has generated thousands of pre-screened leads, and expects recruitment momentum to accelerate as more sites, including new centres in Moldova and Hong Kong, become fully active, keeping interim analysis timing for mid-2026 and full primary endpoint read-out in late 2026 in line with prior guidance, a key marker for the program’s progress and future commercial prospects.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.